Datum Källa Rubrik Typ Alternativ
2023-07-19 Redeye Redeye: Enzymatica Q2 2023 - Waiting for the cold season Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Penser Access Penser Access: Kommande studieresultat i fokus - Enzymatica Pressreleaser Visa Stäng
2023-07-18 Enzymatica Enzymatica AB: Kvartalsrapport Q2/2023: En spännande och viktig tid framöver Rapporter Ladda ner | Visa Stäng
2023-07-18 Enzymatica Enzymatica AB: Interim report Q2/2023: An exciting and important time ahead Rapporter Ladda ner | Visa Stäng
2023-05-16 Penser Access Penser Access: Interview with Enzymatica - Erik Penser Bank - May 16th 2023 Pressreleaser Visa Stäng
2023-05-04 Enzymatica Bulletin from Annual General Meeting of Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Enzymatica Kommuniké från årsstämma i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-04-28 Penser Access Penser Access: Upp till bevis - Enzymatica Pressreleaser Visa Stäng
2023-04-28 Redeye Redeye: Enzymatica Q1 2023 - A step in the right direction Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 28 Apr 2023 | Enzymatica

Redeye: Enzymatica Q1 2023 – A step in the right direction

Redeye provides an update in relation to Enzymatica’s Q1 2023 report. Even if the report was a bit under our expectations, we are positive that the negative effects of the pandemic seem to disappear gradually. The sales during the quarter were SEK13.0m (SEK4.2m), a bit lower than our sales estimate of SEK16.2m, and EBIT came in at SEK-14.4m (SEK-18.1m) compared to our EBIT estimate of SEK-9.7m. We have only made minor changes in our sales and OPEX estimates for 2023. The changes do not render a difference in our valuation; therefore, we reiterate our base case of SEK6.5.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye – Research Powered Investment Banking. www.redeye.se/

2023-04-27 Enzymatica Enzymatica AB: Kvartalsrapport Q1/2023: Stark start på året - Enzymaticas tillväxtresa fortsätter enligt plan Rapporter Ladda ner | Visa Stäng
2023-04-27 Enzymatica Enzymatica AB: Interim report Q1/2023: Strong start to the year - Enzymatica's growth journey continues according to plan Rapporter Ladda ner | Visa Stäng
2023-04-05 Enzymatica Enzymatica AB: Enzymatica publishes annual report for 2022 Rapporter Ladda ner | Visa Stäng
2023-04-05 Enzymatica Enzymatica AB: Enzymatica publicerar årsredovisning för 2022 Rapporter Ladda ner | Visa Stäng
2023-03-31 Enzymatica Notice of Annual General Meeting 2023 in Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-03-31 Enzymatica Kallelse till årsstämma 2023 i Enzymatica AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-02-20 Penser Access Penser Access: Vår syn på bolagets potential är intakt - Enzymatica Pressreleaser Visa Stäng
2023-02-20 Redeye Redeye: Enzymatica Q4 2022 - Lower than our estimates Pressreleaser Ladda ner | Visa Stäng
2023-02-17 Enzymatica Enzymatica AB: Interim report Q4/2022: A year that laid the foundation for growth Rapporter Ladda ner | Visa Stäng
2023-02-17 Enzymatica Enzymatica AB: Kvartalsrapport Q4/2022: Ett år som lade grunden för tillväxt Rapporter Ladda ner | Visa Stäng
2022-12-06 Redeye Redeye: Redeye Initiates Coverage of Enzymatica Analyser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Enzymatica Enzymatica AB: Enzymatica och University of Kent startar studie för att undersöka hur elitidrottare kan förebygga virusinfektioner i de övre luftvägarna Pressreleaser Ladda ner | Visa Stäng
2022-11-03 Penser Access Penser Access: Inte helt ute ur coronatunneln - Enzymatica Analyser Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Kvartalsrapport Q3/2022: En bredare roll för ColdZyme adderar potential för framtiden Rapporter Ladda ner | Visa Stäng
2022-11-02 Enzymatica Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future Rapporter Ladda ner | Visa Stäng
2022-11-01 Enzymatica Enzymatica AB: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells Pressreleaser Ladda ner | Visa Stäng
2022-11-01 Enzymatica Enzymatica AB: Ny studie bekräftar: ColdZyme hindrar virus som orsakar Covid-19 från att fästa vid mänskliga luftvägsceller Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica announces outcome of new rights issue Pressreleaser Ladda ner | Visa Stäng
2022-08-26 Enzymatica Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica publishes supplementary prospectus Pressreleaser Ladda ner | Visa Stäng
2022-08-18 Enzymatica Enzymatica AB: Enzymatica offentliggör tilläggsprospekt Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme blockerar även omikronvarianterna BA.4 och BA.5 Pressreleaser Ladda ner | Visa Stäng
2022-08-16 Enzymatica Enzymatica AB: ColdZyme also blocks omicron variants BA.4 and BA.5 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

25 Apr 2024 | Kvartalsrapport 2024-Q1
7 May 2024 | Årsstämma 2023
8 May 2024 | Årligutdelning
18 Jul 2024 | Kvartalsrapport 2024-Q2
7 Nov 2024 | Kvartalsrapport 2024-Q3
18 Feb 2025 | Bokslutskommuniké 2024